Alessio Malacrida
Overview
Explore the profile of Alessio Malacrida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cavalloro V, Marchesi N, Linciano P, Rossi D, Campagnoli L, Fossati A, et al.
Front Pharmacol
. 2024 Feb;
15:1309766.
PMID: 38370479
The number of patients affected by neurodegenerative diseases is increasing worldwide, and no effective treatments have been developed yet. Although precision medicine could represent a powerful tool, it remains a...
2.
Tarasiuk O, Molteni L, Malacrida A, Nicolini G
Biology (Basel)
. 2024 Jan;
13(1).
PMID: 38275737
Chemotherapy-induced peripheral neuropathy (CIPN) commonly arises as a side effect of diverse cancer chemotherapy treatments. This condition presents symptoms such as numbness, tingling, and altered sensation in patients, often accompanied...
3.
Pozzi E, Ballarini E, Rodriguez-Menendez V, Canta A, Chiorazzi A, Monza L, et al.
Toxics
. 2023 Feb;
11(2).
PMID: 36850969
Chemotherapy-induced peripheral neurotoxicity is one of the most common dose-limiting toxicities of several widely used anticancer drugs such as platinum derivatives (cisplatin) and taxanes (paclitaxel). Several molecular mechanisms related to...
4.
Malacrida A, Deschamps-Wright M, Rigolio R, Cavaletti G, Miloso M
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36675237
Rigosertib is a small molecule in preclinical development that, due to its characteristics as a dual PLK1 and PI3K inhibitor, is particularly effective in counteracting the advance of different types...
5.
Listro R, Malacrida A, Ambrosio F, Rossino G, Di Giacomo M, Cavalloro V, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36361848
The insurgence of drug resistance in treating Multiple Myeloma (MM) still represents a major hamper in finding effective treatments, although over the past decades new classes of drugs, such as...
6.
Malacrida A, Erriquez J, Hashemi M, Rodriguez-Menendez V, Cassetti A, Cavaletti G, et al.
Biochem Biophys Rep
. 2022 Oct;
32:101353.
PMID: 36186735
BackgroundBreast cancer is the most frequent tumor in women. Natural substances represent an important source of innovative therapeutic solutions, eventually integrating or substituting conventional drugs and chemicals. Hibiscus sabdariffa L....
7.
Ballarini E, Malacrida A, Rodriguez-Menendez V, Pozzi E, Canta A, Chiorazzi A, et al.
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077454
Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a frequent adverse event of colorectal cancer treatment. OIPN encompasses a chronic and an acute syndrome. The latter consists of transient axonal hyperexcitability, due...
8.
Malacrida A, Di Domizio A, Bentivegna A, Cislaghi G, Messuti E, Tabano S, et al.
Biology (Basel)
. 2022 Jan;
11(1).
PMID: 35053068
Glioblastoma (GBM, grade IV glioma) represents the most aggressive brain tumor and patients with GBM have a poor prognosis. Until now surgical resection followed by radiotherapy and temozolomide (TMZ) treatment...
9.
Malacrida A, Cavaletti G, Miloso M
Int J Mol Sci
. 2022 Jan;
23(1).
PMID: 35008638
Rigosertib is multi-kinase inhibitor that could represent an interesting therapeutic option for non-resectable patients with cholangiocarcinoma, a very aggressive hepatic cancer with limited effective treatments. The Western blotting technique was...
10.
Malacrida A, Cavalloro V, Martino E, Costa G, Ambrosio F, Alcaro S, et al.
Molecules
. 2021 Nov;
26(21).
PMID: 34771006
Multiple Myeloma (MM) is an aggressive tumor causing millions of deaths every year and currently available therapies are often unsuccessful or correlated with severe side effects. In our previous work...